Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Actas Dermosifiliogr ; 103(10): 910-8, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23154248

RESUMO

BACKGROUND AND OBJECTIVES: Epidermal nevi, which are benign skin growths, have been treated using a range of approaches, with varying results. Topical treatments are ineffective and, while surgical excision is a more definitive treatment, it causes scar formation. In recent decades, epidermal nevi have been treated with various types of laser therapy. We describe our experience with the use of carbon dioxide (CO(2)) laser therapy to treat epidermal nevi and inflammatory linear verrucous epidermal nevi (ILVEN). PATIENTS AND METHODS: Twenty patients (15 with epidermal nevi and 5 with ILVEN) underwent CO(2) laser treatment at our hospital between 2002 and 2010. RESULTS: Response was good (>50% reduction in lesion size) in 50% of cases and excellent (>75% reduction) in 30%. A greater resistance to treatment was observed in patients with ILVEN (only 40% had a good response). Long-term follow-up (at least 18 months) showed a recurrence rate of 30%. The side effects were hypopigmentation (25% of patients) and scarring (20%). CONCLUSIONS: We consider CO(2) laser therapy to be the treatment of choice for epidermal nevi as it is well tolerated and has proven to be safe and effective in the long term. While the response in patients with ILVEN was limited, CO(2) laser therapy might be a good option for selected cases or for palliative treatment since no other treatments have yet proven effective in this setting.


Assuntos
Lasers de Gás/uso terapêutico , Nevo Sebáceo de Jadassohn/cirurgia , Neoplasias Cutâneas/cirurgia , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Nevo/cirurgia , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
2.
Actas Dermosifiliogr ; 103(2): 127-37, 2012 Mar.
Artigo em Espanhol | MEDLINE | ID: mdl-22036021

RESUMO

BACKGROUND: Psoriasis is associated with high treatment costs due to the increasing use of biologic drugs. Phototherapy has been demonstrated to be safe and cost effective for the treatment of psoriasis, although it is limited by the requirement for patients to visit a hospital various times a week. OBJECTIVES: To evaluate the efficiency of home-based phototherapy with narrow-band UV-B radiation compared with biologic drugs for the treatment of moderate to severe psoriasis under normal practice conditions in our setting. METHODS: A retrospective cost-effectiveness study was undertaken in 12 patients with moderate to severe psoriasis. Half of the patients were treated with biologic drugs (2 with etanercept, 2 with adalimumab, and 2 with infliximab) and the other half with home-based phototherapy using a Waldmann UV100L-TL01 lamp. Clinical effectiveness was determined on the basis of achieving a 75% improvement in Psoriasis Area and Severity Index (PASI 75) within 16 weeks of treatment. RESULTS: Treatment was considered to be effective in 5 out of 6 patients (83%) treated with biologics and 4 out of 6 patients (66%) treated with home-based phototherapy. The direct costs required to achieve PASI 75 were 8256€ per patient for biologics and 903€ per patient for home-based phototherapy. The costs associated with effective treatment using biologic drugs in a single patient would provide effective home-based phototherapy for 9.1 patients. LIMITATIONS: The study included a limited number of patients analyzed over a short time period (16 weeks) and the comparison group included multiple treatments with different predicted responses. CONCLUSIONS: Although biologic drugs exhibited greater efficacy, home-based phototherapy was more efficient for the treatment of moderate to severe psoriasis. Home-based phototherapy represents a cost-effective treatment option for patients with psoriasis and may be appropriate for use in the Spanish health care system.


Assuntos
Assistência Domiciliar/economia , Psoríase/radioterapia , Terapia Ultravioleta/economia , Adalimumab , Adulto , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Antirreumáticos/uso terapêutico , Análise Custo-Benefício , Etanercepte , Feminino , Humanos , Imunoglobulina G/uso terapêutico , Infliximab , Masculino , Pessoa de Meia-Idade , Psoríase/tratamento farmacológico , Psoríase/patologia , Receptores do Fator de Necrose Tumoral/uso terapêutico , Estudos Retrospectivos , Índice de Gravidade de Doença , Espanha , Resultado do Tratamento , Terapia Ultravioleta/métodos
3.
Actas Dermosifiliogr ; 103(10): 910-918, 2012 Dec.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-22738854

RESUMO

BACKGROUND AND OBJECTIVES: Epidermal nevi, which are benign skin growths, have been treated using a range of approaches, with varying results. Topical treatments are ineffective and, while surgical excision is a more definitive treatment, it causes scar formation. In recent decades, epidermal nevi have been treated with various types of laser therapy. We describe our experience with the use of carbon dioxide (CO(2)) laser therapy to treat epidermal nevi and inflammatory linear verrucous epidermal nevi (ILVEN). PATIENTS AND METHODS: Twenty patients (15 with epidermal nevi and 5 with ILVEN) underwent CO(2) laser treatment at our hospital between 2002 and 2010. RESULTS: Response was good (>50% reduction in lesion size) in 50% of cases and excellent (>75% reduction) in 30%. A greater resistance to treatment was observed in patients with ILVEN (only 40% had a good response). Long-term follow-up (at least 18 months) showed a recurrence rate of 30%. The side effects were hypopigmentation (25% of patients) and scarring (20%). CONCLUSIONS: We consider CO(2) laser therapy to be the treatment of choice for epidermal nevi as it is well tolerated and has proven to be safe and effective in the long term. While the response in patients with ILVEN was limited, CO(2) laser therapy might be a good option for selected cases or for palliative treatment since no other treatments have yet proven effective in this setting.

4.
J Eur Acad Dermatol Venereol ; 25(6): 710-4, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20569297

RESUMO

BACKGROUND: Keratosis pilaris rubra (KPR) and keratosis pilaris atrophicans faciei (KPAF) are both keratinization disorders characterized by erythema and keratotic follicular papules usually located on cheeks, forehead, chin and eyebrows. Topical keratolytics, vitamin D3 analogues, antibiotics, topical and oral retinoids have been used with limited results. As this condition can be socially very limiting, the need for an effective treatment has led to the use of other technologies such as pulsed dye laser (PDL) or intense pulsed light. OBJECTIVE: The aim of this study was to assess the efficacy and safety of PDL in patients with KPR or KPAF. METHODS: Ten patients with KPR or KPAF were treated with two to seven sessions of PDL at 595-nm wavelength. Laser therapy was performed using a spot size of 7 or 10mm, a pulse duration of 0.5 or 1.5ms and a fluence from 5 to 9J/cm(2) . Two dermatologists evaluated treatment effectiveness by means of photographs of the patients before starting and after finishing the therapy. RESULTS: Complete resolution of erythema was achieved in three patients; clearance of erythema was >75% in the other seven patients. Transient purpura was present in all patients for about 2weeks and one patient presented postinflammatory hyperpigmentation for 7months. CONCLUSION: We consider that PDL is a good option for the treatment of KPR and KPAF. A marked reduction in erythema is achieved in all patients with a low incidence of side effects.


Assuntos
Anormalidades Múltiplas/cirurgia , Eritema/cirurgia , Ceratose/cirurgia , Lasers de Corante/uso terapêutico , Adolescente , Adulto , Criança , Doença de Darier , Sobrancelhas/anormalidades , Feminino , Humanos , Lasers de Corante/efeitos adversos , Masculino , Púrpura/etiologia , Adulto Jovem
5.
An Med Interna ; 23(11): 543-5, 2006 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-17222072

RESUMO

We report the case of a male adolescent affected by Burkitt Lymphoma which presented as acute abdominal pain and rapid growth mass. It was characterized by computed tomography and diagnose was confirmed by bone marrow study. Two different chemotherapic regimens were used because of unfavourable evolution, but they were not successful. We consider some other causes of abdominal bulky in childhood, especially primary tumours and non tumoural diseases.


Assuntos
Dor Abdominal/etiologia , Linfoma de Burkitt/complicações , Dor Abdominal/diagnóstico , Dor Abdominal/tratamento farmacológico , Adolescente , Antineoplásicos/uso terapêutico , Linfoma de Burkitt/diagnóstico , Linfoma de Burkitt/tratamento farmacológico , Humanos , Masculino , Estadiamento de Neoplasias , Tomografia Computadorizada por Raios X , Resultado do Tratamento
8.
Rev Clin Esp ; 206(7): 340-2, 2006.
Artigo em Espanhol | MEDLINE | ID: mdl-16831382

RESUMO

The organism whose cells come from different individuals is called chimera. It is frequently observed in nature: pregnancy, organ transplantation or transfusion are considered chimeric cell sources. It has been involved in autoimmune diseases development such as scleroderma, because of similarities between it and graft versus host disease, long term persistence of fetal cells in women and the finding of greater number of chimeric cells in affected women than healthy ones. It is not strictly a disease but might be considered helpful in non-invasive prenatal diagnosis and damaged organs regeneration.


Assuntos
Quimerismo/estatística & dados numéricos , Transplante de Órgãos/estatística & dados numéricos , Doenças Autoimunes/epidemiologia , Feminino , Humanos , Masculino , Gravidez , Diagnóstico Pré-Natal
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA